Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

NCT06070012 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Uveal Melanoma

Interventions

DRUG: Tebentafusp

Sponsor

Diwakar Davar

Collaborators

[object Object]